Invasive fungal infection incidence and risk factors in patients receiving ibrutinib in real‐life settings: A nationwide population‐based cohort study

Abstract Background Data on the risk of invasive fungal infections (IFI) with ibrutinib treatment are scarce. Objectives This study aimed to determine IFI incidence and risk factors in ibrutinib‐treated patients in real‐life settings. Methods We constituted a cohort of ibrutinib incident users in the French National Healthcare Database. All patients ≥18 years with a first dispensing of ibrutinib between 21 November 2014 and 31 December 2019 were included. Patients were followed from the cohort entry date until IFI, ibrutinib discontinuation, death, or 31 December 2020, whichever came first. The cumulative incidence function method was used to estimate the probability of IFI accounting for competing risk of death. A multivariate cause‐specific Cox proportional hazards model was used to assess independent IFI risk factors. Results Among 6937 ibrutinib‐treated patients, 1‐year IFI cumulative incidence was 1.3%, with invasive aspergillosis being the most frequent. Allogenic or autologous stem cell transplantation (ASCT) (hazard ratio [HR] 3.59, 95% confidence interval [1.74; 7.41]), previous anticancer treatment (HR 2.12, CI 95% [1.34; 3.35]) and chronic respiratory disease (HR 1.66, [1.03; 2.67]) were associated with higher risk of IFI. Besides neutropenia and corticosteroids, use of anti‐CD20 agents was significantly more frequent in patients having experienced IFI (HR 3.68, [1.82; 7.45]). Conclusions In addition to patients with ASCT history, severe neutropenia or treated with corticosteroids, our findings support active surveillance of IFIs in those with chronic respiratory disease, previously treated, or treated with anti‐CD20 agents in combination with ibrutinib. Further studies are needed to optimise IFI prophylaxis in these patient subgroups.